title: Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation.
abstract: In this paper, we investigate the pharmacokinetics and effect of doxorubicin and cisplatin in vascularized tumors through two-dimensional simulations. We take into account especially vascular and morphological heterogeneity as well as cellular and lesion-level pharmacokinetic determinants like P-glycoprotein (Pgp) efflux and cell density. To do this we construct a multi-compartment PKPD model calibrated from published experimental data and simulate 2-h bolus administrations followed by 18-h drug washout. Our results show that lesion-scale drug and nutrient distribution may significantly impact therapeutic efficacy and should be considered as carefully as genetic determinants modulating, for example, the production of multidrug-resistance protein or topoisomerase II. We visualize and rigorously quantify distributions of nutrient, drug, and resulting cell inhibition. A main result is the existence of significant heterogeneity in all three, yielding poor inhibition in a large fraction of the lesion, and commensurately increased serum drug concentration necessary for an average 50% inhibition throughout the lesion (the IC(50) concentration). For doxorubicin the effect of hypoxia and hypoglycemia ("nutrient effect") is isolated and shown to further increase cell inhibition heterogeneity and double the IC(50), both undesirable. We also show how the therapeutic effectiveness of doxorubicin penetration therapy depends upon other determinants affecting drug distribution, such as cellular efflux and density, offering some insight into the conditions under which otherwise promising therapies may fail and, more importantly, when they will succeed. Cisplatin is used as a contrast to doxorubicin since both published experimental data and our simulations indicate its lesion distribution is more uniform than that of doxorubicin. Because of this some of the complexity in predicting its therapeutic efficacy is mitigated. Using this advantage, we show results suggesting that in vitro monolayer assays using this drug may more accurately predict in vivo performance than for drugs like doxorubicin. The nonlinear interaction among various determinants representing cell and lesion phenotype as well as therapeutic strategies is a unifying theme of our results. Throughout it can be appreciated that macroscopic environmental conditions, notably drug and nutrient distributions, give rise to considerable variation in lesion response, hence clinical resistance. Moreover, the synergy or antagonism of combined therapeutic strategies depends heavily upon this environment.
authors.affiliation: Department of Mathematics, University of California, Irvine, CA, USA.
authors.forename: John P
authors.initials: JP
authors.lastname: Sinek
authors.forename: Sandeep
authors.initials: S
authors.lastname: Sanga
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Zheng
authors.forename: Hermann B
authors.initials: HB
authors.lastname: Frieboes
authors.forename: Mauro
authors.initials: M
authors.lastname: Ferrari
authors.forename: Vittorio
authors.initials: V
authors.lastname: Cristini
mesh_terms: D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000493:pharmacokinetics / Q000494:pharmacology; D003198:Computer Simulation; D004273:DNA, Neoplasm / Q000378:metabolism; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000494:pharmacology; D005260:Female; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D004317:Doxorubicin; D002945:Cisplatin
references.citation: Int J Cancer. 2000 Apr 1;86(1):101-7
references.pmid: 10728602
references.citation: Neuroimage. 2007;37 Suppl 1:S59-70
references.pmid: 17475515
references.citation: Clin Cancer Res. 1999 Jul;5(7):1703-7
references.pmid: 10430072
references.citation: Biophys J. 2005 Dec;89(6):3884-94
references.pmid: 16199495
references.citation: Cancer Chemother Pharmacol. 1991;27(6):417-22
references.pmid: 2013111
references.citation: J Theor Biol. 2003 Jan 21;220(2):201-13
references.pmid: 12468292
references.citation: Cancer Res. 2001 Sep 15;61(18):6624-8
references.pmid: 11559524
references.citation: Cytometry. 1995 Aug 1;20(4):307-14
references.pmid: 7587718
references.citation: Recent Results Cancer Res. 1984;95:134-49
references.pmid: 6396756
references.citation: Endocr Relat Cancer. 2002 Sep;9(3):171-82
references.pmid: 12237245
references.citation: J Cancer Res Clin Oncol. 1994;120(5):293-7
references.pmid: 8126058
references.citation: Blood. 1997 May 15;89(10):3745-54
references.pmid: 9160680
references.citation: J Mol Biol. 1974 Jun 25;86(2):469-89
references.pmid: 4416620
references.citation: Drug Metab Dispos. 2002 Feb;30(2):183-90
references.pmid: 11792689
references.citation: Nat Rev Cancer. 2006 Aug;6(8):583-92
references.pmid: 16862189
references.citation: Expert Rev Anticancer Ther. 2006 Oct;6(10):1361-76
references.pmid: 17069522
references.citation: Cancer Res. 2006 Feb 1;66(3):1597-604
references.pmid: 16452218
references.citation: Bull Math Biol. 2004 Sep;66(5):1039-91
references.pmid: 15294418
references.citation: Cancer Res. 1984 Jan;44(1):238-44
references.pmid: 6197161
references.citation: Bull Math Biol. 2003 Jul;65(4):609-40
references.pmid: 12875336
references.citation: Bull Math Biol. 2002 Jul;64(4):673-702
references.pmid: 12216417
references.citation: Eur J Cancer. 1992;28(1):82-6
references.pmid: 1567698
references.citation: J Natl Cancer Inst. 1986 Jul;77(1):247-52
references.pmid: 2425117
references.citation: Bull Math Biol. 1998 Sep;60(5):857-99
references.pmid: 9739618
references.citation: Cytotechnology. 1998 Sep;27(1-3):95-111
references.pmid: 19002786
references.citation: J Theor Biol. 2003 Nov 21;225(2):257-74
references.pmid: 14575659
references.citation: Ann Biomed Eng. 2008 Feb;36(2):254-61
references.pmid: 18172768
references.citation: Mol Cell Biol. 1989 Aug;9(8):3284-91
references.pmid: 2552289
references.citation: Biomed Microdevices. 2004 Dec;6(4):297-309
references.pmid: 15548877
references.citation: Br J Cancer. 2005 Aug 8;93(3):302-9
references.pmid: 16052217
references.citation: J Cell Biol. 2000 Mar 6;148(5):863-70
references.pmid: 10704438
references.citation: Clin Cancer Res. 2002 Mar;8(3):878-84
references.pmid: 11895922
references.citation: J Math Biol. 2003 Mar;46(3):191-224
references.pmid: 12728333
references.citation: Biochemistry. 1989 Jan 10;28(1):274-82
references.pmid: 2706251
references.citation: Neuroimage. 2007;37 Suppl 1:S120-34
references.pmid: 17629503
references.citation: Br J Cancer. 1988 Sep;58(3):330-4
references.pmid: 3179185
references.citation: Microvasc Res. 1996 May;51(3):327-46
references.pmid: 8992232
references.citation: J Control Release. 2001 Jul 6;74(1-3):7-25
references.pmid: 11489479
references.citation: Bull Math Biol. 2005 Mar;67(2):211-59
references.pmid: 15710180
references.citation: Cancer Treat Rev. 2003 Aug;29(4):297-307
references.pmid: 12927570
references.citation: Math Biosci. 2003 Feb;181(2):177-207
references.pmid: 12445761
references.citation: Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14212-7
references.pmid: 11724924
references.citation: J Math Biol. 2000 Nov;41(5):455-75
references.pmid: 11151708
references.citation: Biochim Biophys Acta. 1990 Nov 12;1055(2):117-25
references.pmid: 2242381
references.citation: Cancer Cell. 2003 Apr;3(4):347-61
references.pmid: 12726861
references.citation: Ann Thorac Surg. 2001 Oct;72(4):1173-8
references.pmid: 11603432
references.citation: J Pharmacokinet Biopharm. 1998 Dec;26(6):717-33
references.pmid: 10485082
references.citation: Nat Rev Drug Discov. 2005 Apr;4(4):307-20
references.pmid: 15789122
references.citation: Nat Rev Cancer. 2005 Mar;5(3):161-71
references.pmid: 15738981
references.citation: AAPS PharmSci. 2001;3(2):E15
references.pmid: 11741266
references.citation: Anticancer Res. 1996 Mar-Apr;16(2):741-9
references.pmid: 8687123
references.citation: Exp Cell Res. 1999 Jul 10;250(1):131-41
references.pmid: 10388527
references.citation: Nature. 2004 Feb 19;427(6976):695
references.pmid: 14973470
references.citation: Cancer Res. 1974 Oct;34(10):2814-22
references.pmid: 4369924
references.citation: Neoplasia. 2003 Mar-Apr;5(2):161-9
references.pmid: 12659689
references.citation: Biochem Pharmacol. 1998 Nov 1;56(9):1209-17
references.pmid: 9802333
references.citation: J Theor Biol. 2007 Apr 21;245(4):677-704
references.pmid: 17239903
references.citation: Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8782-8
references.pmid: 16361566
references.citation: Science. 1990 Mar 23;247(4949 Pt 1):1457-61
references.pmid: 2108497
references.citation: J Theor Biol. 2006 Aug 7;241(3):564-89
references.pmid: 16487543
references.citation: Biochem Pharmacol. 1993 May 25;45(10):2079-85
references.pmid: 8512589
references.citation: Neoplasia. 2005 Jul;7(7):705-13
references.pmid: 16026650
references.citation: Biochim Biophys Acta. 1989 Sep 19;1013(2):109-17
references.pmid: 2765536
references.citation: Cancer Chemother Pharmacol. 1990;26(3):198-204
references.pmid: 2357767
references.citation: Cancer Chemother Pharmacol. 1984;12(1):59-63
references.pmid: 6690077
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6772-9
references.pmid: 16203763
references.citation: Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3497-504
references.pmid: 7909602